Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

RedHill Biopharma (RDHL) Return on Capital Employed (2016 - 2023)

RedHill Biopharma has reported Return on Capital Employed over the past 10 years, most recently at 234.47% for Q2 2023.

  • Quarterly Return on Capital Employed rose 876690.0% to 234.47% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 234.47% through Jun 2023, up 876690.0% year-over-year, with the annual reading at 321.15% for FY2025, 70702.0% down from the prior year.
  • Return on Capital Employed was 234.47% for Q2 2023 at RedHill Biopharma, down from 108.68% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 108.68% in Q4 2022 and troughed at 9001.37% in Q2 2022.
  • The 5-year median for Return on Capital Employed is 58.17% (2021), against an average of 982.89%.
  • Year-over-year, Return on Capital Employed plummeted -905954bps in 2022 and then skyrocketed 876690bps in 2023.
  • A 5-year view of Return on Capital Employed shows it stood at 92.79% in 2019, then tumbled by -32bps to 62.82% in 2020, then tumbled by -226bps to 79.32% in 2021, then soared by 237bps to 108.68% in 2022, then tumbled by -316bps to 234.47% in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Return on Capital Employed are 234.47% (Q2 2023), 108.68% (Q4 2022), and 9001.37% (Q2 2022).